We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Should You Add Marinus (MRNS) Stock to Your Portfolio Now?
Read MoreHide Full Article
Marinus Pharmaceuticals’ (MRNS - Free Report) epilepsy medicine, Zalmy (ganaxolone) oral suspension, which was approved in the United States in 2022, has been witnessing strong sequential sales growth and enjoying robust payer coverage one year into the launch. Zalmy is approved for treating seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD), a rare form of genetic epilepsy.
Marinus’ commercial partners in the EU, China and some other regions have also made notable progress in terms of Zalmy’s launch.
The company is also evaluating ganaxolone for the treatment of other rare genetic epilepsies like tuberous sclerosis complex (TSC) and refractory status epilepticus (RSE).
The year 2024 is expected to be a catalyst-rich year for Marinus. The company expects its interim analysis, with top-line data readout from the RAISE study evaluating IV ganaxolone for RSE, to be available in the second quarter of 2024. Over 75% of patients required for an interim analysis are now enrolled. Full enrollment for the interim analysis is expected to be concluded in the first quarter of 2024.
Top-line data from the phase III TrustTSC study on ganaxolone for TSC is expected in mid-2024. Marinus is currently the only product in phase III development for this indication. The company expects to complete both the RAISE and TrustTSC studies in 2024. Approval for these expanded indications will significantly expand Zalmy’s eligible patient population.
The ganaxolone franchise could prove to be an important long-term growth driver for Marinus as the epilepsy market is relatively an orphan market.
Marinus Pharmaceuticals’ stock has risen 70.1% in the past year against a decrease of 7.4% for the industry.
Image Source: Zacks Investment Research
The consensus estimate for 2024 loss has narrowed from $2.43 per share to $2.27 per share over the past 90 days. The company has a Zacks Rank #2 (Buy).
In the past 60 days, estimates for Regeneron’s 2024 earnings have risen from $41.57 per share to $43.97 per share. Regeneron’s stock has surged 27.8% in the past year.
Regeneron beat estimates in each of the trailing four quarters, delivering an average earnings surprise of 12.34%.
In the past 60 days, estimates for Puma Biotechnology’s 2024 earnings per share have improved from 62 cents to 69 cents. In the past year, shares of PBYI have risen 5.9%.
Earnings of Puma Biotechnology beat estimates in three of the last four quarters while missing the same on the remaining occasion. PBYI delivered a four-quarter average earnings surprise of 76.55%.
In the past 60 days, the consensus estimate for Fusion Pharmaceuticals’ 2024 loss has narrowed from $1.41 per share to $1.38 per share. Fusion Pharmaceuticals’ stock has risen 201% in the past year.
Earnings of Fusion Pharmaceuticals beat estimates in three of the last four quarters while missing the same on the remaining occasion. FUSN delivered a four-quarter average negative earnings surprise of 2.90%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Should You Add Marinus (MRNS) Stock to Your Portfolio Now?
Marinus Pharmaceuticals’ (MRNS - Free Report) epilepsy medicine, Zalmy (ganaxolone) oral suspension, which was approved in the United States in 2022, has been witnessing strong sequential sales growth and enjoying robust payer coverage one year into the launch. Zalmy is approved for treating seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD), a rare form of genetic epilepsy.
Marinus’ commercial partners in the EU, China and some other regions have also made notable progress in terms of Zalmy’s launch.
The company is also evaluating ganaxolone for the treatment of other rare genetic epilepsies like tuberous sclerosis complex (TSC) and refractory status epilepticus (RSE).
The year 2024 is expected to be a catalyst-rich year for Marinus. The company expects its interim analysis, with top-line data readout from the RAISE study evaluating IV ganaxolone for RSE, to be available in the second quarter of 2024. Over 75% of patients required for an interim analysis are now enrolled. Full enrollment for the interim analysis is expected to be concluded in the first quarter of 2024.
Top-line data from the phase III TrustTSC study on ganaxolone for TSC is expected in mid-2024. Marinus is currently the only product in phase III development for this indication. The company expects to complete both the RAISE and TrustTSC studies in 2024. Approval for these expanded indications will significantly expand Zalmy’s eligible patient population.
The ganaxolone franchise could prove to be an important long-term growth driver for Marinus as the epilepsy market is relatively an orphan market.
Marinus Pharmaceuticals’ stock has risen 70.1% in the past year against a decrease of 7.4% for the industry.
Image Source: Zacks Investment Research
The consensus estimate for 2024 loss has narrowed from $2.43 per share to $2.27 per share over the past 90 days. The company has a Zacks Rank #2 (Buy).
Marinus Pharmaceuticals, Inc. Price and Consensus
Marinus Pharmaceuticals, Inc. price-consensus-chart | Marinus Pharmaceuticals, Inc. Quote
Other Stocks to Consider
Some other top-ranked biotech companies are Regeneron Pharmaceuticals (REGN - Free Report) , Puma Biotechnology (PBYI - Free Report) and Fusion Pharmaceuticals (FUSN - Free Report) . While Regeneron and Puma Biotechnology sport a Zacks Rank #1 (Strong Buy), Fusion Pharmaceuticals has a Zacks Rank of 2. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for Regeneron’s 2024 earnings have risen from $41.57 per share to $43.97 per share. Regeneron’s stock has surged 27.8% in the past year.
Regeneron beat estimates in each of the trailing four quarters, delivering an average earnings surprise of 12.34%.
In the past 60 days, estimates for Puma Biotechnology’s 2024 earnings per share have improved from 62 cents to 69 cents. In the past year, shares of PBYI have risen 5.9%.
Earnings of Puma Biotechnology beat estimates in three of the last four quarters while missing the same on the remaining occasion. PBYI delivered a four-quarter average earnings surprise of 76.55%.
In the past 60 days, the consensus estimate for Fusion Pharmaceuticals’ 2024 loss has narrowed from $1.41 per share to $1.38 per share. Fusion Pharmaceuticals’ stock has risen 201% in the past year.
Earnings of Fusion Pharmaceuticals beat estimates in three of the last four quarters while missing the same on the remaining occasion. FUSN delivered a four-quarter average negative earnings surprise of 2.90%.